alexa Allogeneic Stem Cell Transplantation for Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors- What are the Limitations?
ISSN: 2157-2518

Journal of Carcinogenesis & Mutagenesis
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Review Article

Allogeneic Stem Cell Transplantation for Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors- What are the Limitations?

Sehar Afreen1* and Zakariya Al Safran2

1Medical Imaging Department, King Fahad Specialist Hospital-Dammam, Dammam, Kingdom of Saudi Arabia

2King Fahad Specialist Hospital-Dammam, Dammam, Kingdom of Saudi Arabia

*Corresponding Author:
Sehar Afreen
Research Assistant
Medical Imaging Department
King Fahad Specialist Hospital-Dammam
Dammam, Kingdom of Saudi Arabia
Tel: (+966) 5410 35255
Fax: (+966) 3 842 409
E-mail: [email protected] or [email protected]

Received Date: December 31, 2012; Accepted Date: February 20, 2013; Published Date: March 05, 2013

Citation: Afreen S, Safran ZA (2013) Allogeneic Stem Cell Transplantation for Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors- What are the Limitations? J Carcinogene Mutagene S14:001. doi: 10.4172/2157-2518.S14-001

Copyright: © 2013 Afreen S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

 

Abstract

The treatment strategies for chronic myeloid leukemia have changed dramatically with the advent of tyrosine kinase inhibitors. Since they provide an excellent opportunity for complete cytogenetic and molecular remissions, they are recommended as a first line therapy. Although a small fraction of patients has been reported to remain in molecular remissions after discontinuing of tyrosine kinase inhibitors, there is an increased likelihood of disease relapse after these drugs are discontinued. Therefore, allogeneic stem cell transplantation remains the only cure at present. However, toxicity of preparative regimens, development of graft versus host disease, infectious complications, and increased rates of relapse in advanced phases of the disease limit the safety and efficacy of this approach. This review highlights the major limitations of transplantation and the areas of studies required to improve the clinical outcomes.

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords